-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BeDlkUlgclyfUU/hK6CnpNBxexxKBc7+QX8C46h4Bb2DrkwHiu42JQ6T0X/5Xua+
 muXA3NtB9a3ruXhDOJCtfw==

<SEC-DOCUMENT>0000950123-10-027212.txt : 20100323
<SEC-HEADER>0000950123-10-027212.hdr.sgml : 20100323
<ACCEPTANCE-DATETIME>20100323161104
ACCESSION NUMBER:		0000950123-10-027212
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100323
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100323
DATE AS OF CHANGE:		20100323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		10699469

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c98238e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): March 23, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, New Jersey<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">The information set forth under this &#147;Item&nbsp;2.02. Results of Operations and Financial Condition,&#148; including the
exhibit attached hereto, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific reference in such filing.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Attached as Exhibit&nbsp;99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc., dated March&nbsp;23, 2010,
announcing certain financial results for the fourth quarter and the year ended December&nbsp;31, 2009.


<P align="justify" style="font-size: 10pt; text-indent: 4%">The Company will conduct a conference call to review its financial results on Tuesday, March&nbsp;23, 2010, at 4:30
p.m., Eastern Time.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>Financial Statements and Exhibits.</B></DIV></TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The following exhibit is furnished with this Report:</DIV></TD>
</TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated March&nbsp;23, 2010.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="center" style="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Paul McBarron</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul McBarron</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Executive Vice President &#151; Finance,<BR>
Chief Financial Officer and Chief<BR>
Operating Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="justify" style="font-size: 10pt">Date: March&nbsp;23, 2010

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c98238exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c98238p9823801.jpg" alt="(CYCLACEL PRESS RELEASE GRAPHIC)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND<BR>
FULL YEAR 2009 FINANCIAL RESULTS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>&#151; Conference Call Scheduled March&nbsp;23, 2010 at 4:30 p.m. Eastern Time &#151;</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>BERKELEY HEIGHTS, NJ &#151; March&nbsp;23, 2010 </B>&#151; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;) announced today financial results for the fourth quarter and
year ended December&nbsp;31, 2009. Cyclacel also provided an overview of its recent achievements and
planned 2010 milestones.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Company&#146;s net loss for the fourth quarter of 2009 was $4.3&nbsp;million or $0.18 per share, compared
to a net loss of $7.9&nbsp;million or $0.39 per share for the fourth quarter of 2008. For the year
ended December&nbsp;31, 2009, the Company reported a net loss of $19.6&nbsp;million or $0.88 per share,
compared to a net loss of $40.4&nbsp;million or $1.98 per share for the year ended December&nbsp;31, 2008. As
of December&nbsp;31, 2009, cash and cash equivalents totaled $11.5&nbsp;million.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Fourth Quarter 2009 and Recent Highlights</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Raised approximately $15.6&nbsp;million in gross proceeds through two &#147;registered direct&#148;
offerings in January&nbsp;2010 and warrant exercises;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Submitted a Special Protocol Assessment (SPA)&nbsp;to the U.S. Food and Drug Administration
(FDA)&nbsp;for a randomized Phase 3 registration study for sapacitabine in elderly patients with
acute myeloid leukemia (AML)&nbsp;following a Type A End of Phase 2 meeting with the FDA;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Presented 1-year survival data with sapacitabine from a Phase 2 randomized trial in elderly
patients with AML at the 2009 American Society of Hematology (ASH)&nbsp;annual meeting;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Presented interim results with sapacitabine from a Phase 2 trial of older patients with
myelodysplastic syndromes (MDS)&nbsp;at ASH demonstrating activity in patients refractory to
hypomethylating agents; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Elucidated the mechanism of action, target profile and selectivity of Cyclacel&#146;s cyclin
dependent kinase (CDK)&nbsp;inhibitors, including seliciclib, in recent peer-reviewed publications
demonstrating activity in highly resistant cancers as well as therapeutic potential in other
proliferative diseases.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;Cyclacel is developing sapacitabine as an innovative, orally-available agent to serve the unmet
medical need of elderly patients with AML,&#148; said Spiro Rombotis, President and Chief Executive
Officer of Cyclacel. &#147;The Company achieved an important milestone during the first quarter of 2010
with the submission of an SPA for a randomized Phase 3 registration study of sapacitabine in
elderly patients with AML. In addition, the Company continued to work towards advancing other
indications for sapacitabine, including MDS and lung cancer both of which are in Phase 2, and also
realizing value from the rest of its pipeline.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Cyclacel&#146;s Milestones for 2010</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Response from the FDA regarding the SPA for the pivotal trial of sapacitabine in elderly
patients with AML;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Report MDS Phase 2 interim data with sapacitabine at the American Society of Clinical
Oncology (ASCO)&nbsp;annual meeting;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Report non-small cell lung cancer (NSCLC)&nbsp;Phase 2 interim data with sapacitabine;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Report top line results from APPRAISE NSCLC Phase 2b trial with seliciclib; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Present preclinical data with Cyclacel&#146;s next generation CDK inhibitors at the American
Association for Cancer Research (AACR)&nbsp;annual meeting.</DIV></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Fourth Quarter and Full Year 2009 Financial Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the fourth quarter of 2009, Cyclacel reported a net loss of $4.3&nbsp;million or $0.18 per share,
compared to a net loss of $7.9&nbsp;million or $0.39 per share for the fourth quarter of 2008. Total
research and development (R&#038;D) expenses in the fourth quarter of 2009 were $2.6&nbsp;million compared to
$3.2&nbsp;million in the fourth quarter of 2008. The decrease in R&#038;D expenses in the fourth quarter of
2009 compared to the fourth quarter of 2008 was primarily due to lower employment and related costs
following the workforce reduction in the second and third quarters of 2009 and to a lesser extent
the completion of patient enrollment in October&nbsp;2008 of the Phase 2 trial for AML.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Total selling, general and administrative expenses (SG&#038;A) amounted to $1.8&nbsp;million in the fourth
quarter of 2009 compared to $4.0&nbsp;million for the fourth quarter of 2008. The decrease is primarily
due to lower employment and related costs following the workforce reductions.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the year ended December&nbsp;31, 2009, Cyclacel reported a net loss of $19.6&nbsp;million, or $0.88 per
share, compared to a net loss of $40.4&nbsp;million, or $1.98 per share for the year ended December&nbsp;31,
2008. Total net sales of Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> products were $0.9&nbsp;million in 2009 compared to
$0.8&nbsp;million in 2008. Total R&#038;D expenses for the year ended December&nbsp;31, 2009 were $9.8&nbsp;million
compared to $18.9&nbsp;million for the year ended December&nbsp;31, 2008. This $9.1&nbsp;million reduction is due
to the implementation and execution of our announced cost containment efforts in September&nbsp;2008
which eliminated or reduced the costs of all programs other than those related to sapacitabine
clinical development. Total SG&#038;A expenses for the year ended December&nbsp;31, 2009 were $8.6&nbsp;million
compared to $15.4&nbsp;million for the year ended December&nbsp;31, 2008. The decrease was a result of the
cost saving measures first established in September&nbsp;2008 and then continued during the second and
third quarters of 2009 which were primarily related to the workforce reductions. During 2008,
there was a charge for goodwill and intangible impairment of $7.9&nbsp;million with no corresponding
charge in 2009 recognized as the assets were fully impaired during the third quarter of 2008. Cash
used in operations for the year ended December&nbsp;31, 2009 was $15.2&nbsp;million compared to $29.9&nbsp;million
in 2008.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Company recorded a gain on the change of valuation of warrants of $3.5&nbsp;million during 2008
compared to a charge of $0.3&nbsp;million during 2009. This was a result of an overall lower stock price
during 2009 compared to 2008 stock price levels. The Company recorded interest income of $0.1
million in 2009 compared to $1.4&nbsp;million in 2008. This reduction resulted from the reinvestment of
maturing short-term investments into cash and cash equivalents in 2009, which have a lower interest
yield, for security purposes together with lower average cash, cash equivalent and short-term
investment balances during 2009 compared to 2008. During 2008 there were unfavorable foreign
exchange movements of approximately $4.5&nbsp;million compared to $0.1&nbsp;million during 2009. The decrease
is attributable to the change in accounting for the Company&#146;s intercompany loans. As a result,
starting in the fourth quarter of 2008, the Company now recognizes changes in intercompany loans as
other comprehensive income on the consolidated balance sheet as the repayment of intercompany loans
is not expected in the foreseeable future.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cash and cash equivalents totaled $11.5&nbsp;million as of December&nbsp;31, 2009. Cyclacel expects its cash
resources, together with the proceeds from recent financings, will be sufficient to meet its
anticipated short-term working capital needs and fund current operations, including on-going
sapacitabine clinical trials, for at least the next twelve months.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In November&nbsp;2009, Cyclacel amended the Kingsbridge Capital Limited Committed Equity Financing
Facility (CEFF)&nbsp;and subsequently raised approximately $1.0&nbsp;million in December&nbsp;2009. As the Company
did not declare dividends on its preferred stock for several quarters during the fiscal year 2009,
the Company will not be able to use its Registration Statement on Form S-3 upon the filing of its
Annual Report on Form 10-K for the year ended December&nbsp;31, 2009, which covers the shares subject to
the CEFF and therefore it may not be able to access the CEFF until such time as an effective
registration statement covering such shares be in place.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Company also announced that certain senior executives of the Company have adopted a trading
plan under Rule&nbsp;10b5-1 of the Securities Exchange Act of 1934, as amended, as part of their
individual long-term strategy for asset diversification and liquidity. Rule&nbsp;10b5-1 permits
corporate officers, directors and others to adopt written, pre-arranged stock trading plans when
they are not in possession of material, non-public information. These plans allow insiders to have
shares sold for their accounts over a period of time, in order to minimize the market effect of
stock sales, regardless of any material, non-public information they may receive after adopting
their plans.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Conference call and Webcast Information:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel will conduct a conference call on March&nbsp;23, 2010 at 4:30 p.m. Eastern Time to review the
quarterly and year-end 2009 results. Conference call and webcast details are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Conference call information:<BR>
US/Canada call: (877)&nbsp;493-9121/ international call: (973)&nbsp;582-2750<BR>
US/Canada archive: (800)&nbsp;642-1687 / international archive: (706)&nbsp;645-9291<BR>
Code for live and archived conference call is 63824576

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel
website at <U>www.cyclacel.com</U>. The webcast will be archived for 90&nbsp;days and the audio replay for 7
days.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel is a biopharmaceutical company dedicated to the discovery, development and
commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious
disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine
(CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of
acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. Seliciclib
(CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the
treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with
sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients
with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary markets directly in the U.S.
Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis, Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges for xerostomia.
Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and
oncology based on a portfolio of commercial products and a development pipeline of novel drug
candidates. Please visit <U>www.cyclacel.com</U> for additional information.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Forward-looking Statements</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended
utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk
that product candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel
will not obtain approval to market its products, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated with reliance on collaborative
partners for further clinical trials, development and commercialization of product candidates. You
are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable
words to be uncertain and forward-looking. For a further list and description of the risks and
uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and
other periodic and current filings that have been filed with the Securities and Exchange Commission and are available
at <U>www.sec.gov</U>. Such forward-looking statements are current only as of the date they are made, and
we assume no obligation to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Contact for Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investors/Media:<BR>
Corey Sohmer, (908)&nbsp;517-7330<BR>
<U>csohmer@cyclacel.com</U>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and
Cyclacel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks
of Sinclair Pharma plc.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the three</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Year ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception) to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>December 31</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="18"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Revenues:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration and research and
development revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Product revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">248</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">222</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">838</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,748</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(35</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,636</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">187</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">877</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">911</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,384</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating expenses:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of goods sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">114</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">429</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">545</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">974</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,151</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,592</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,869</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,766</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">170,179</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,017</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,354</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,538</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71,846</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Goodwill and intangibles impairment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,590</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,934</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,934</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">489</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,634</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total operating expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,872</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43,075</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,215</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253,567</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,621</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,313</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42,198</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18,304</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(245,183</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Costs associated with aborted 2004 IPO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,550</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payment under guarantee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,652</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,652</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of derivative </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(308</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(148</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(299</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,408</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrant</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(44</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(44</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign exchange gains/(losses)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">137</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,501</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(144</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,187</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,380</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">102</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,643</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(74</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(318</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(177</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,634</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">440</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(176</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,214</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,676</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss before taxes</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(8,181</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(4,489</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(42,135</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(20,518</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(239,507</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">238</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,749</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">948</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,222</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(7,943</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(4,337</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(40,386</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(19,570</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(222,285</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividends on Preferred Ordinary shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38,123</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss applicable to common
shareholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(7,943</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(4,337</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(40,386</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(19,570</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(260,408</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per share &#151; basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.18</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1.98</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.88</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,433,129</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,691,329</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,433,129</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,196,840</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">As of</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">As of</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">December 31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">December 31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,220</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,493</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,731</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,369</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property, plant and equipment (net)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">901</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deposits and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">195</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,466</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LIABILITIES AND STOCKHOLDERS&#146; EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">754</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,709</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued and other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,801</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,709</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrants liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">342</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current portion of other accrued restructuring charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,029</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,062</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,627</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,822</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other accrued restructuring charges, net of current</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,062</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long term payables</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">626</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,315</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,822</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preferred stock, $0.001 par value; 5,000,000 shares
authorized at December&nbsp;31, 2008 and 2009, respectively;
2,046,813 shares issued and outstanding at December&nbsp;31,
2008 and 2009, respectively. Aggregate preference in
liquidation of $20,673,000 at December&nbsp;31, 2008 and
December&nbsp;31, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common stock, $0.001 par value; 100,000,000 shares
authorized at December&nbsp;31, 2008 and 2009, respectively;
20,433,129 and 25,743,363 shares issued and outstanding
at December&nbsp;31, 2008 and 2009, respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional paid in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">223,377</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">226,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated other comprehensive loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit accumulated during the development stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(202,715</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(222,285</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,642</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,644</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,466</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c98238p9823801.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c98238p9823801.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&D",0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`.'\5_$'P[X0!BOKAKC42FZ/2[+;)=D,"5:;Y@EK&
MW]Z5E)!RH:O7RW)<=F+YJ,/9T$[.K.\8>:CUD_**?FT>'FW$&79.N2O4=3$6
MO&A3LYZ[.6J4$^\FK[I,\2N_C1XOU69XO#NBVUM&&.Q8[6ZU>\"G@;VCVQ*>
M1_RRZ]S7U=+A7+,+%2QN*E)];SA0A\D[R_\`)CXFKQIF^*FX9=@H4XK9*$Z]
M1=KVM'JOL%&3QI\9;8>?-#K,<(.<2>%K58<$XP2NEAPN?]L'WK:.5<+2]R$J
M#EY8N?-]WM;7^7R,)9UQG2]^<,1&"Z/`P4?PH)V^?S+^E_'/7[*80ZYI-E>Q
MHV)?LRS:=>IR<_NY6DC8C^Z4CSCK6.(X0P4X\V#Q,Z+^SS<M2F_FE&2];OT-
M\+QSCZ$U#'82G6BGKR*5&HN^C<HZ=N6/J>[>%_&WA_Q;"6TJZVW4:AI].N0(
M+Z`'JQAW$21Y_P"6D1=>1D@G%?'YAE.-RN5L13_=MVC4AK3E\[+E?]V23\C[
MO*\[R_-H7PE6U6*O*C.T:L/^W;ZK^]%N/FGH==7FGKA0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0!Y+\3/'LOAN*'0]#'G>(]355B6-/->QAF8Q1S"(`[[N5\K#&0
M>A=A@`/])D&31QLI8O%>Y@<.];OE5225W&^EH16LY?\`;JU;:^2XFS^66PA@
M<"N;,L2DHI+F=*,G92Y5O4D]*<?^WFK))^4_\(OH7A"U37_B---JVNZB6N;3
MPU%<%III&.3-J=QNW/\`.<.2PC4_*/-;Y1]'_:&+S&H\%D4(X7!T/=GBG&T8
MKM2CLM-M.9[^ZM3Y3^R\#D]*./XCG+%X[$/GIX*,KRDWO*M*]WK\3NHIZ>^]
M#3&H_$C4[)9M,@TCX>>&_E^SF1K/1(O+P"K^=<QFXF8H,[HXHU;L.:Y_89%A
MJKA7G6SK'+XK*==WZKEB^2.O24I-'4L3Q)B:*GA:>'X>RW3DNZ>&C:VCYIKV
MDM-;QC%,Q/+\4+*QMOB]H\]TK$K%_P`)/J4*,V>0'N;=;?'/<X/:NN^7\J4^
M&:U.GW^J4FTO2$N?]3A4<TC-^RXOP\JJ>D?KM:*;]9Q5/KWLR/5-6\3:?'%%
MX_\`#UEXETF7$<.K;+87&W&`VG^(]+^4R@$D),6SC!'H\/AL!5<GDN-GE^)A
MJZ-Y*/I4PM76WG&UNA.*Q>9X>,(Y_EU/,L)+2->T.>W>EC*&G-Y3O?9HATWP
M/?ZA<VFO?#G4S<6D=RNY[NYBT_5O#\ZD.T.H+D+<1!"2)(0PD7(VGG-U\VHX
M:G5P>>8?V=3E=E"+G1Q$=N:G_*[[J5G%]2,-D6(Q%6CCN&\2YT8S6LYQI5\+
M/=QJJZ4E;:4+J<;KE?7VWP1\9/`7CS6]3\,^'=:-]K.BQ.]RC6=Q:PWD5O(E
MO=7FFR3(JW-LEPZ*2-I_>(P!1@Q_,G:[Y5RQN[+LGL?L$4U&*D[R25VMKVU:
M^9ZK2&%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!0U34K71M.N]3O'\NULH6FE;T`P%4?
M[3.RJ/=A6V'H5,36I8>BKU*DN6*_%_<KMG/BL32P6'K8FL^2E0BY2?Y+U;:2
M\V?/?@\1I;^(OB_XHC$LOF7+Z-;R=%<-]G0P!N`V\Q64)YVA)&[@C[7,[\^!
MX8RY\D4H*O)::6YGS6\KU9]VXKN?GV3J,:>8\7YG'FE>;P\'T:?(N6_GRT:;
M^RE)^97M[>ZLS:^+==LAKWC[Q9-N\+:%.-UMIEM@-#>S0D@1Q0PLA4-@(NWD
M.7>.YSIU%4RW!U?J639;&V+Q$=)59?:A%]7*2=[:R=]URQ>5.G5H.EFV.H?7
ML_S:5\#A9*\*,-XU)1Z1A%IQ3LHJVTG*46W.BP76IR1Z['J_Q(\71@/>Z;87
M1L?#FA;\G[+=7PVI#M)`*(4`P05!Y+IXJ5+#IX-T<ARQZ4ZE2'/B:_\`?A3U
M;OW=[]V@J8*%3%2CCE7XCS>.M2C2FZ6$PM_L3JJRC;JH\JWND]2-]!:3?"WP
MS\+7:1A@]IH?BL-K,2_[/EWKM+*HY_U;=.E5'&*%I+/L71<K6G7PEJ#?SA%1
M3_Q+U)E@+WA_JU@JJC>]/#8Z^(BO^W:LG*2_P/T*_A[1KA[J:/P1>3+;K*D7
MB?P+XMVQFVM7<)-+*CJ(KNV7)`E18YT.WJ3@UC<53A2C+-J45*SEA<?@_M32
MNDFO>A)[N+<J<E?H9Y=@JLJTX9'5E[/F4<9EF.LN2#:4FT[0J0U^**C5B[=6
M176M:\)]`/[.%KX>\0>&Y?$L]CX\N'E,[6UQ"UH4M;A]1GBEM]-6QEN6$ULL
MA^9=A.</\3C<PQ>.E3GBJOM'2CRQT44D]7I%)7;U;ZGZ)E^5X'*H5*>!H^PC
M6ES2]Z4G?HKR;=HIV2V1ZOX)^"OP_P#A[X@U;Q-X9TN>UU35DFA=I[R:XALK
M:XG2YGM=/ADXMX))HXV()=@(U4,%&*XCT-OD>KT`%`!0`4`%`!0`4`%`!0`4
M`%`!0!6N;RULE5[J>*V5BP0R.$W%(WE?;Z[8T=CZ!23P*`)T=7571E='4.CJ
M0RLK`%65AP5((((]:`'4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`>2?&N\>U\$26\9*G4]5TZPXX&-TM\0WHI^Q?RKZ7A2DI9LI
MO;#T:E3\J>G_`(,/DN-:SI9)*G'3ZS7I4O\`TJKKY?NRIXCT6,6WPT\"H`MI
M->PRW\*\">VT.Q%S=!CP"))I&8\<E@>U:8'%2Y\^S?\`Y>0A)4WMRRKU.6%O
M2*27EH8YC@HQI<-9%%<M&=2,JL5IS0PU/GG?RE*3;\W<BF>ZGU'Q5XAM-HU2
M?5;;P!X5<C,>G*K1PWUY$,80B>6YF)&,?92O0FJ@J=*AEV!J:8>G1EF.+6SJ
M-IRIP??W5&*7]^^Y$W5GB,US"C98J=>&58%VTHJ\8U:D>UI2G-M?R-;-FMHG
MA"QOXI+)C/'X6TVYFM(-/CED@?Q%J-M(8]2UK7+B-EDO%>\26..$OL/E,[`@
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MXQ3ERIV5][7>IWNA^&]`\,07-KX>T?3M%M[N\FO[J#3K6*TCGO)\>=<RK$H#
M2MM49/90!@#%<QV;>1KS2Q6\4L\\B0P01O+-+(P2.**-2\DDCL0$144DDD``
M$F@#P>R^+?BOQD]S<_"_X=R^(?#MM<RVL?BKQ!KMOX8TO5)(&9)VT>V>UN;J
M\MQ(K()S&BE@00N#@`T-7^*>O>$U\%WGC3P7_P`([I/B+5YM`UR]37+?4T\+
MZG)*\6D7%S+:VHAN-*OL!O/WQ&$;A(-P`<`Z3XA^/SX+3P_I^F:9_;_BGQ9K
M,&C^'=!6Z^Q_:#D2ZAJ%S<"&7[-IUE:YDFF\M@N],X!+*`8WB7XJS6/B1O`O
M@WPO>^.?&=I90WVK6=E>6^EZ+H$-PH:!M8UN]4QVTDH972!8VD9'4X!8`@%S
M3_%_CZTTWQ+?^,?`5CH4>AZ#?:U9W&F^*+;6;34I;.WDN'TYE6R@GLYMJ<RM
M&R'G;G'(!T_@+Q0?&G@WPYXK-F-..NZ9!J)LA-YXMC/G,0F,<?F`8^]L7.>E
M`%'XD>-X_A[X6N->%@^K7S7=AI>C:-%+Y$VK:OJEU':V=C%)Y;[&9G=R=C86
M)N*`$^&OCF+X@^%;;Q`+!])O5N[_`$O5]'EF$\VDZMIEU):WEE+*$3>P*I("
M44E9EXH`Y?7?BO>'Q+?^#/A]X1O/'7B#1U3^WIDU&UT7P]H$LJEH;74=8NU<
M/?,`Q-M#&[C!!.Y650"27QYXXT+POXQU[QCX!M=%?POHLNKV7]G^)[;5K#6S
M#%/)+:QRI913V$D?E)N::`@B8%<[30!E>%?'_P`6/$UOX?U5?A;I%IX?UQ--
MO?[0_P"$YM)+BVTK4/*E:\^P?V:KR31VLAD\C<I8KMR">`#JM"^(3:Q\2_&O
MP]_LL6R^$-.T2_75!=;S>_VQ;07!C-KY*^0(_.V[O,?=MS@9H`ZOQ!X<L_$$
M5O%=-)']F<NA0D#/F03KN4$9VW-K;2@9PQAV.&CD=6`-BSM8K&SM+*#=Y-G;
M06L.\Y;RK>)88]QP,ML09-`%F@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`\_N-8\4ZOJ^NV?A1O#]I;^$=0MM+U.'Q#9Z
MC<3>(-5N-$TCQ(;"PO=-U"%?#.GKIFM:9#_:DMGK<C3WET?[,6/38_[8`-B+
MQ?HWV6XN+M[C39K#6/#WAS5;&[@:2ZTKQ%XGC\//I6C7+Z<;JVN+AF\5:'&]
MQ97%U:(UV2;G9#*\8!S&N?$S2(_"WC+5O#=Q]JU/P]X/\1>)])75-(UNPTK7
M(='TZ:YCU'1;N\MK*+Q5X?\`M#:>);[1;JY@$>IV3?:$6_MGF`.GN?&7AVSU
ME=!GO+A;TW%I92SII6KS:-8ZAJ"PMI^E:IXC@L7TG2=8NQ=V'V?3[V]@N9SJ
MNG"*)SJ-J+@`KZ?X]\)ZC]M:#5?L]O8:?<ZPU_JECJ6B:5>:)9[#>:]HNK:Q
M9VMEK_A^!)K6275-,GN[..._LI7F$=[;M,`8^I?$&R.DB\T$7`O8/%'@'1KW
M3O$6A:_X?U"WT_Q?XTT;PW)?_P!CZY::;?"WDM;S5!:7OE-;27.G3H&F-G<0
MJ`6/$NJ>*1XI\.>&?#-_X?TO^T_#_BS7;V]UW0-1\08_X1_4?!NGVUK:VVG^
M)M%\CS?^$FN)'DDEF_X]HU5!N9J`.8F^(^H:!<VFG^))='9K'XCMX&UK5=/T
MS4[:/4X[KX77/Q!TMM!T!=2U&[@UB;4;K1]'BL5N=6EO94<6T8GU""WM0-O*
MQV]QX[\,VMAIVH"ZU"\35?MGV*RTCP_XAUO6S_9LRVNK?:?#NCZ5<ZI8?V;?
M/%97_P!JLX?L-Y/%9W?DW4J1.`5[_P")'@G3))(I]?MW:'PN/&K&PM[[5(SX
M1:UU>\'B.*;2[6XCFT?R=%O%^TQLR"6:P@)\_5;".\`*_P#PM'P)_P!!S_IO
M_P`@S6/^0/\`]#=_R#_^1`_ZF[_D!?\`41H`V+GQEX=L]9709[RX6]-Q:64L
MZ:5J\VC6.H:@L+:?I6J>(X+%])TG6+L7=A]GT^]O8+F<ZKIPBB<ZC:BX`*^G
M^/?">H_;6@U7[/;V&GW.L-?ZI8ZEHFE7FB6>PWFO:+JVL6=K9:_X?@2:UDEU
M33)[NSCCO[*5YA'>V[3`!:^._#-S;37'VK4+'[/J&A:9-::QX?\`$.@ZK%<^
M)M5@T30)&T;6M*M;\:??:M/]EAO_`+-]E:2VNU\[_0KGR`#/UCXB:1I/B#0/
M#L,&H:A=ZKXP?P=J#V>EZW-#HM__`,(>?%\3W$]II,]O)OM+O1,AIX42#4+R
M[:7R=&OQ;@!!\1/#-MI7A^[O]9^V?VMX?TK7Y=4TOPYXA72K;2M2MA+!XBUJ
M.."^_P"$'\/W7EWDT4VOW=O'''8WH>Y?^SKJ2(`V+GQEX=L]9709[RX6]-Q:
M64LZ:5J\VC6.H:@L+:?I6J>(X+%])TG6+L7=A]GT^]O8+F<ZKIPBB<ZC:BX`
M.8T+XF:0_A;P9JWB.X^QZGX@\'^'?$^K+I>D:W?:5H4.LZ=#<R:CK5W96UY%
MX4\/FX74!%?:U=6T!CTR]8W#K87+P@'I]`'F&G_$S2+>TA'B.X^S:M?^(/B/
MIVC:5H^D:WJM_JMAX%\<7WAEVT_3-+MKZ[O]0BT\:;=7,-NCOL-[=I"EI9W!
MM0#?U#Q[X3TW[$T^J^?;WVGVVL+?Z78ZEK6E66B7N\V>O:UJVC6=U9>'_#]P
MD-U)%JFISVEG)'87LJ3-'97#0@'84`%`'D?QIMR_A"WN0#LTS7]*O9%`ZQM]
MHLCD]%&Z\4Y/I[U]+PK-0S.=/9U\/5IKIK[M3_VQGR7&=+FRBG46V&Q5&J_2
MTZ?RUJ+YF[X@1%\5?#[4\CR!=:SIX?J@DU+2'EMMI'\3M:LH/3#&N/!-_P!G
M9UAUI+DHU+;.U*LE+[N>[.[,(Q6:\/XK["GB*2?2];#N4+><G3:7J9MG;K91
MW4;<#2/B+-?W6_`\NVU=VF@N,#_EGC5H3N.``CD_=-;U9NI*FX_\Q&6QIPMU
ME17+*/K^YEIU;7<Y:-)4(U8OW5@\WE5G?2T,0W*,_3]_%WZ)2[,[?0(Q:Z>+
M'D26%Q=6\JM@,#]HDECD.,<2PRQ2@]Q)ZYKRL8^>M[5:1JQA)6V^%)K_`+=D
MG%^A[F7Q5+#JAM+#SJ0DNOQRDG_V]&2DO)FG/;07*+'/$LJ1S0W"*PX6:WE6
M:&08Z,DJ*P]U%<AVD]`!0!YM\8H-0N?A9X_@TM9GOI/"NKK#';DB9@+20S)'
MMP26@$HP.2"0.M`#/@U>Z/??"WP)-H31?V?'X;TNV"1,I\B[MK:."_@FVD[;
MA+U)Q(#SNR3G.2!M\CJ_%GAC2?&7AW5_#&MP"?3=8LY+2=>`\3-AH;J`G_5W
M,$ZQS1O_``O$I[4`?.7[/&DZEKMYKGC+Q=JIUW6_!MU=_"OP[*\7EI8:3X>\
MH7FH!69MVI:C)-'YTY/F%82I8B0@`&S\"YH;;QK\=]*U`B+Q/_PL:\U.XBG=
M1=3>'KI"=`FC0X9[1(6DVL,JHN8P<>8,@;>1[3X]_P"1&\9?]BKX@_\`33=T
M`<C\"./@]\.^V/#-C[8SOH`\I^)OC73)OC-X0T2_L?$&J:#\.K9_%6K0>'="
MU#7G_P"$JU&%H?#L%Y#IT4AMQ;6AENU=P,M+M'.2`"+X5^,M,M?C-XUT#3[+
M7M*T'XA0)XOT:W\0:%?^'Y5\2642P^(X+2WU"*-ITN(=MT70$`Q;>U`;>1T'
M[-LL4%E\2=(O2D?BJR^)GB2?Q!"Z^7>,+N2(V-U(&P\EO(L<_EOC;A6`H#;R
M/2/C1_R2?XA_]BGK/_I))0!YO\(_#_Q:3PS\/KZ3X@Z"_A4:)H%P=!7PA%'>
MG2#8P,NG?VM]MW"X$!5#<>5RR[MO."!M\@\#_P#)RGQH_P"Q=\%?^FVRH`^E
M:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`//[C1O%.CZOKMWX47P_<V_B[4+;5-3F\0WFHVTWA[5;?1-(\-F_L+'3
M=/E7Q+I[Z9HVF3?V7+=Z'(L]G=#^TVCU./\`L<`Y@Z3I]W\6M`\G6+C6M1\.
M>%UN?$LZSZ9)=:?K.@6FH:/X277[?3+.&'2;C6]&^*WCN_,!@M!=-HEI+8I#
M;V-W%=`;!%X,\:-\-M7^&\Q\+V]C:_#B_P#`>A:E%?:K=76MW1T$:#I>M:O"
MVDV\?A6W6&$RW%A;_P#"0,S:B!'=J-/_`.)H`'B_P%XK\0^);2_AU6W.DV?B
MCP1X@MEN?$/BJQCM-,\.:YH&H:CX97PAI4D>B:G<2SZ=J6K1>(-4^VW'FWT>
MF?8X8K:TU*P`+&G^"O%,O@&]^&FJ7'A_3M$@\`7/@'3M:T^74=7U74]^BIH%
MGXAO=-N+33(-!\JTBDGDTJ*ZUCSI+]8UU&!;`OJ0!GV7PXUC[)J$L]MI^F:G
M>^(/AC=NL_COQWX_F?2O`7CBV\5SB3Q%XOBCEA\RWFU*.UTVVTR"..=GEGO9
MEOPNF`;'7^)?`>E>*_%/AS5-?T?P_KNB:)X?\6:>^G:[I]MJFW5=<U'P;<:?
M>VMG>V<T`\JTT+58GF+QR)]LC5%=99#&`6+OP=:VT_@&'PY8:/H>C>$/%&H:
MW+I=C:QZ9:I:WWA'QGHKQZ;96-J(%N'U;Q+!<2*1"K+]ID+F3"2@;>5CD+OP
M%XK_`+)MM,LM5MXX6\4?$75;NUMO$/BKPU'&OC#QIJGB'0M>;4O"DECJFK7&
MCZ;?W$,WAPWFG66H2ZI(SZC`^FVEPP!GVGPOU^W\%Z_X<:\T<WVJ?`CPA\+[
M>5;B]-K'K^@:5XWL;R\F<Z>)$T=YO$MB8I5B>9EBG+VZ%4$H&QU'BSP5JNN_
M\+.^QW&GQ_\`"9_#"P\%:5]IEN4^SZK:_P#"PO,N+_RK23R=//\`PEFG;7A\
M^0^3<YB&R/S@-C'\7^`O%?B'Q+:7\.JVYTFS\4>"/$%LMSXA\56,=IIGAS7-
M`U#4?#*^$-*DCT34[B6?3M2U:+Q!JGVVX\V^CTS['#%;6FI6`!8T_P`%>*9?
M`-[\--4N/#^G:)!X`N?`.G:UI\NHZOJNI[]%30+/Q#>Z;<6FF0:#Y5I%)/)I
M45UK'G27ZQKJ,"V!?4@#/L_AQK']G:W/+;:?INMW>H>`M0LX+GQWX[\>_;/^
M%>^*?^$OL+*_\4^+HEGTS3[V[>>S6&QT9_L/VBYOF;4FN$L[0#8L6GA#QH^L
M6WB*^M/"]M>M\5X?&=YIEIXAU6]M;?0&^%"_#6X%MJ<WA.UDN]828O?I:O8V
MT,BJ(6NXRQE4`/#G@SQIX0M?#Z:.?"][?#X<>`?`>LW&I7VJP6NBW7@J/6P-
M:TRSM=):3Q5;SS>([IOL$]UX=;;I42?:T-^SZ>`'B_P%XK\0^);2_AU6W.DV
M?BCP1X@MEN?$/BJQCM-,\.:YH&H:CX97PAI4D>B:G<2SZ=J6K1>(-4^VW'FW
MT>F?8X8K:TU*P`,]?ASXKL=`\$Z9I<VCVFLZ%X'\-^%KKQ+I_B3Q5H%UH^IZ
M%9?9X]6?3=,MFL?B?H]M=32W5GH/B"#3;>-DO8Y)7CU^Y6R`/7],U*ZO;WQ#
M:W&F7&GPZ-K$.FV%U-YGEZW:RZ!H>KOJ=IOMXU%NE]JMYIQ\MYU\W2)LR!]\
M4(!Q'AOP5JNC:]I>J7-QI[V]C_PN;S4@EN6F;_A8GQ)T?QCHOEK):(I\C3-/
MFBNLNNR=T6+SXR95`V^1C^'/!GC3PA:^'TT<^%[V^'PX\`^`]9N-2OM5@M=%
MNO!4>M@:UIEG:Z2TGBJWGF\1W3?8)[KPZVW2HD^UH;]GT\`]?MFNFC8WD-O;
MRBXNU2.VN9+J,VJ74R6,S2RVELR7$UDMO--"(V6&662%)KA(EGF`V\K%B@#'
MU_1K;Q!H]_HUW_Q[WL/E,1U1E=98I`/59HT;_@-=.#Q53!8JCB:6DZ,KI=TT
MU)?--KYG'C\%3Q^#KX*KI3KQLVNC34HM>DDG\CB-+CNO$G@M--9UMO$WAFXB
MM"7.#;:]X?D1K.9^_D74<<+%L8:*\?&:]?$.G@,U=>*<L!CXN:2^UA\2GSQ7
M]ZFW)6Z2@KGAX6-7,<ECAFU3S/+)QIZ_8Q6$DG3D_P"[5BHMO9PJ.QH+<Q7L
M/_"106<DEM>6K:3XLT;86NK=[4NCL8%^9[NQDDGC=`-TL$H>/)2,/@Z<J$OJ
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MWZ%ZUO-D:?:E>SC:2."T>_EBCN[N63/6W4#RV9ONIG<1DE$`Q6-2E[S]DU4E
M%.4U33Y()?WGNN[V_O.YO2K<L5[5.C%N,:;JRC&I4D_[J^%M[1^)ZWC$U*YS
MJ$(!!!`((P0>00>H(]*`/$+GX$Z%:W]]J'@WQ1XT^';:G<-=:A8>$=:6TT:X
MN)!^\G&DWEK<06\K9ZPK&HXVJ,4`>H^&=!_X1G1[;2/[7UO7#`\\CZIXAOCJ
M.JW,EQ,\\AN+KRX]RJTA5%"@(BJHX6@#%\">`]-^']GK=EIEW?7<>N>)=5\3
MW#7Q@+PWFKM$T\$'D0Q@6R>4NT,&;DY8T!L9/C+X2^&/&.JVOB-I]9\.>*K*
M`VMMXH\*ZE)HVLBVY*6]S-&K1WD"MT6:-R`-H(7B@/P(]%^&#:99>(+34_'7
MCGQ2=?T:ZT.5_$6K6]U'86MW%)%)-I]I!90P0W963F5D<G:`<@G(!RGA[X&7
M?AF/2;/3/BU\38M*T9[7[+HW]IZ6FG&VMI5E%BT,>EJ1:N`495(.UR`10!Z1
MX1\#:=X0O?%FIVUW>W^I>,=>EU[5;R_,!E#&,0VFGVX@AC"6%I#N2%&#,`[9
M8YH#8B\7>`=-\6ZMX/UR:\OM,U7P5K)U?2[NP^SAY%FC6*\TZZ$\,@>QN8U1
M9%78Q"\,,G('X&)XK^$'AKQ+K7_"46E]K_@_Q7Y(MY?$7A#5'T>_O(5"JD6H
MH(Y(+]5154&6(M@*-V%``!';?">-?#_BK0-7\;^./$J^+-+?2+N[U_5;>[?3
M[9TF0MI5K'91V]G*WGL6;RVW[4W#Y:`_`P=!^">H>'3H\5E\7/B<=,T5[%;;
M1Y-3TS^SGL[%H_+TZ6%-+4FS:*,1,JLIV,0"#R`"?7O@C%JOC/7/&^E>/?&_
MA+5?$$&GVVHQ^'+S3[6WDATVT@M+=#YVGRR,,0!\,Y^9VQ@'%`'I?A+P]=>%
M](72KOQ'KOBB9;B>?^U?$5Q#<ZDRS%2+<R6\$2>3'@[!LR-QY-`'34`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!PVM6-[HF
MJGQ7HMO)<K)%%;^)=(@'[W4+*#/D:E9)D!]4LT9@$_Y;1$Q@AE3/KX2K2Q.&
M_LW%35)Q;EA:TM%2G+XJ4WTI57K?[$[2V;/#QM"M@<5_:V"INHI1C#&8>/Q5
M:<?AK4UUKT5=<O\`R\IMQW42=(8]0*>*?"%[:F6\B074#EQIVLI%\JI>*B^9
M9:E"`8UN`AD3!CF1U`5(<GA[Y=F5&<8TF^22M[6@WJW#[,Z4_B<+\LOBA)-W
M=J$<1RYID]:'-62YXNZHXA1T2J)+FIUH:Q53EYH_!4C)*RIB]TJ"=FN&U#P7
MJ,CEITE$<>FW,N/GE$SI+IMWDY_>*8Y3G+8/%:^RQ#@HTU3S2A%6BXW=6"Z+
ME3C7A;^5IP72Z,?;86G-NHZN2XF3O)2M&C.767,U/#3O_,G&H^MGH7GO0JEI
M/&NEQ0*&)D2+2HY`ISAO-DN7CR/7RL>U8JCJHQRFJY]$W6:_\!45+7_$;NMR
MJ\L[H0@NJC03_P#`G.4?_)2E;7VGF<RZ':ZAXHU3YHUU*Y9UL+7=]X?VG/$E
MM;0X))2PBD=AQL.16LZ-:,.7%5*>78=6;I02]I+_`+A1;J2EYUI12[HPIU\/
M[3FP-*KFF*U2K3;5*%]_WTU&E"/=4(RD_P"5G5VLD]G;0#6+VS^UW$_EJ8E%
MK;F:9B8K.U660O,5'RJ6)=]I8@9P/.J1A.<_JM&<:5.-[/WI*,?BG/E24;[N
MWNQO:[W?K4I5*-."QE>G[6<K+E7LX<TG[M.FI.\K;*[YI;V6RTJP.D*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@#DKSPPT5W-JOAR^;0M3N&\R[C6(7&D:G)@_
M/J.F[D!G/0W,#PS<G<S]*]*ECTZ4,-C:*Q>'IJT'?DK4EVI5;/W?^G<U*'9(
M\FME;A6GBLNKO`8F;O42CS8>L^]6C>*YG_S]IN%3NY;"+K&OV@,.L>%YKA5^
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MH^E"A*I-^2E.G?N6M.\-+!=IJNL7LNMZQ&"(+JY18;33PXPZ:5IT9,5D",`R
M$R3,!\TI!Q6=?'MTGAL+26#PK^*$6W.IV=:H[2GW4?=@ND37#98J=:.*QE>6
M-QD?AG-*-.C?=4**]VG?K+WJCZS>QU%>>>H%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`-9E16=B%5%+,QX"JHR2?8`4`<;I'Q#\&:Y?
M1:;I6O6US>7'G?9(S%=VZ7IML_:!8SW-O'%>M'@[A`\A&#GI0!VE`",0H+,0
MJJ"23P``,DGV`H`XO2?B+X*UJ^@T[2]>M;B[NFF2S0Q7=O'>O;Y\]+&XN;>.
M&\=,'<L,CD8/'%`':T`%`'(:%X]\)>)+U].T+6(M0NXDFD>.*VOHT5;=UCF_
M?36J1%E=U!4/GG@4`=?0!5O;VTTVTN;Z_N8;.RLX7N+FYN'6*&WAC4L\DCL0
M%4`?X<F@#*\/^*-"\46\UUH-^+ZWMY%BED%O=6^UW02)A;N")G5HR&5E!4@@
M@T`;]`&1K>O:/X:L'U/6[^#3;&-XXC-,6^::4[8H8HHU:2:9SG;'&K,<'`X-
M`$ND:OIVN6$&IZ3<?:;&X\P13>5/;DF*1HI%,5Q'')&RR(RD,BG(-`&E0`4`
M%`"$X!/0#GZ8H`XK2_B-X*UB^@TW3=?M9[NZDEALU,5W;Q7DUOGSH;*ZN+>.
M"\E3!RD,CMQTH`[:@`H`X_1?'OA'Q#J#Z7HFLQ7U]&)R\,5M?(J_96"3@SRV
MJ1;D9@"N_//`-`'84`4M1U&RTBPN]3U&X6TL+""2YN[APY2"",;I)&6-68@#
MGY5)]J`'6%]::G96NHZ?,MS97L$5U:3H&5)H)D#QR*'56`9"#R`>>E`%N@#`
M\0>*-!\*6T%WK^HQ:;;7-PMI;R21SR>;<LCR+"B6T4C%RB.1\O;UH`O:5JMA
MK5A!J>ES_:;&Y#F";RIH-X21HG_=7$<<BX=&'S(.F1P:`-&@##U[Q+H7A>VM
M[O7M2M]+MKFZCLK>2X\S$EU,&:.)1$C')",22`H`R2*`-L$8!!XZ@CICL10`
MM`'-^(/%_AOPK]E&O:K#8/>F06D)CN)[B<1`-,\=M:0RRF*,,"TFS:N1DC-`
M&_!-%<0PW$#B2&>*.:%P"`\4J!XW`8`@%&!Y`/-`$M`''ZIX^\(Z+JZZ#J6L
MQ6VKLMNXL1;7TTH2[;;;N3;VKHJNW&2P`[XH`["@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
MK7G_`!YW?_7M/_Z*:@#YG^$G@[4=?T/P+K6H:G:PZ-X5U37-1TG3;6RE34)K
M^:^N87:_OI9ROV=7#,L<4*[@0&)Z@`^H:`(+G_CWN/\`KC+_`.@-0!\:_#9W
MGE^%6G>(@+/0(-0\0:IX6O+5'62Z\2P:C<HVF:M/*2+>,*3)$L*KYI=%8]<`
M;'VC0`AZ'Z'^5`'S5^S_`*D@M+W2F\2VK/\`;];N$\*?8HH[VW_TZ+=JC7N[
MS9(G#;?+*[1O!!XH#;Y'TM0!Q_CZRT34/!VO6/B*^;2]&N++R[W4$W;K,&:(
MPW`55;<%N1"2NTAAD'@DT`<-\&O$>LZS9:[IM]>1:WI7AV^M],T+Q1!9/81Z
MU9I"5QY1`61X$CB!D4<^;R6/S$`]IH`\J^+EEH5UX>L)-9\1CPI/I^LVNHZ%
MK#1-/%!K-I%<2VRS6ZHPFC9!+D''*C!)PK`&C\+/$6N>*/!MAJ_B"V2WOY)K
MN(31P/:QZA;P3&.#44MG`,*SJ"<``':64!6``!Z)0`4`%`#'^X_^ZW\C0!\7
M?#QWF?X8Z;XB"VGAN/Q#KVJ>'KZU1EEN/%-I?RB+2]5GD)%M;L',D0B5?-9U
M1CP<`?@?:E`!0!\T?`34D3^U=*;Q-:AVU?Q!<1^$C91)>H1=P;M5^W;O->%E
M!3RMNWG.>*`V\K'TO0!PGQ/_`.2>>,0!_P`P#4,`?]<6["@"G\*M:TG5/!6@
M6VFW]O=SZ3H^E6>I10,2]G="S3,$ZD#9(-K<>QH`]'H`\$^/<GD:9X*F%VFG
M>1XWTJ4W\D0FBL-D5P_VR2%N)(X<>85.`0A!ZT`>N^&;Z/4-#T^[CUJW\0B2
M)P=9M;>.T@OG262-Y8[:%F2$!E*%5)&4)[T!M\C>H`^;OBI!=^,?%C>%K'1K
MS7+?P]X4U.\N8K.>SM39ZWK\36NE74CWD\2R?9X83*(T)<^<<+UH`]2^%_B!
MO$G@;0-0F)^VPV@T[458%72_TUC97.\'HSM")/I**`._H`^?/C-=6.@ZCH_B
MO3?$L>B^-M'TZ[32-+GLWOH=?L+F<1S6`@$9"2O(SJ'5MWS<XVAE`/;=!O+R
M_P!%TF^U"T_L^^N].L[F\LOF'V2XG@22:##?,NUV(PW(Q@\@T!MY6-:@#YFU
M?4DTKX[ZC+)XFM/#$<OAO08&DO+**[755:\B)TF$S,HMII@"1*I++MX!H`^F
M:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`:B)&H6-511G"HH51GDX"@`9-`#J`"@"/R80%
M411A4;<B[%`1LYW*,85L\Y%`$E`!0!$D$,;;HX8D;!&Y(T5L'DC*@'!-`;>5
MB6@!&52"K`%2,%6`((/4$'@B@!$1(E5(T6-$&%1%"*H]%50`H^E`;>5AU`#)
M(HY%V2QHZ=2DB*R\<CY6!'6@!P````P!P`.``.@`H`6@`H`*`"@"/R80JJ(H
MPJ-O5=BA4?KN48PK9)Y'-`;>5B2@`H`B2"&-MT<,2-S\R1HK<]>5`/-`$M`"
M%0058`J1@J0""#U!![4`,CBBAR(HTB!.2(T5,GU.T#)H`DH`8\<;@+(B,`<A
M756`/J`PX/-`"HBQJ$1515Z*@"JN>3A0`!S0&WE8=0`T(BLS!55FQN8*`QP,
M#<0,G`]:`V\@1$C!$:+&,EB$4*,GJ2%`Y/K0`Z@"-XHG9&>.-FC.Z-G16:-O
M[R$C*'W&*`)*`"@")H(6;>\,3.,89HT+#'3YB,B@"6@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@"EJ.GP:G:2V-RURD,NS<;2[NK"X&R19%\NZ
MLY8IH\LHSM<9&5.02"`<Q_P@6A?\_'B/_P`*SQ+_`/+6@`_X0+0O^?CQ'_X5
MGB7_`.6M`!_P@6A?\_'B/_PK/$O_`,M:`#_A`M"_Y^/$?_A6>)?_`):T`'_"
M!:%_S\>(_P#PK/$O_P`M:`#_`(0+0O\`GX\1_P#A6>)?_EK0`?\`"!:%_P`_
M'B/_`,*SQ+_\M:`#_A`M"_Y^/$?_`(5GB7_Y:T`'_"!:%_S\>(__``K/$O\`
M\M:`#_A`M"_Y^/$?_A6>)?\`Y:T`'_"!:%_S\>(__"L\2_\`RUH`/^$"T+_G
MX\1_^%9XE_\`EK0`?\(%H7_/QXC_`/"L\2__`"UH`/\`A`M"_P"?CQ'_`.%9
MXE_^6M`!_P`(%H7_`#\>(_\`PK/$O_RUH`/^$"T+_GX\1_\`A6>)?_EK0`?\
M(%H7_/QXC_\`"L\2_P#RUH`/^$"T+_GX\1_^%9XE_P#EK0`?\(%H7_/QXC_\
M*SQ+_P#+6@`_X0+0O^?CQ'_X5GB7_P"6M`!_P@6A?\_'B/\`\*SQ+_\`+6@`
M_P"$"T+_`)^/$?\`X5GB7_Y:T`'_``@6A?\`/QXC_P#"L\2__+6@`_X0+0O^
M?CQ'_P"%9XE_^6M`!_P@6A?\_'B/_P`*SQ+_`/+6@`_X0+0O^?CQ'_X5GB7_
M`.6M`!_P@6A?\_'B/_PK/$O_`,M:`#_A`M"_Y^/$?_A6>)?_`):T`'_"!:%_
MS\>(_P#PK/$O_P`M:`#_`(0+0O\`GX\1_P#A6>)?_EK0`?\`"!:%_P`_'B/_
M`,*SQ+_\M:`#_A`M"_Y^/$?_`(5GB7_Y:T`'_"!:%_S\>(__``K/$O\`\M:`
M#_A`M"_Y^/$?_A6>)?\`Y:T`'_"!:%_S\>(__"L\2_\`RUH`/^$"T+_GX\1_
M^%9XE_\`EK0`?\(%H7_/QXC_`/"L\2__`"UH`/\`A`M"_P"?CQ'_`.%9XE_^
M6M`!_P`(%H7_`#\>(_\`PK/$O_RUH`/^$"T+_GX\1_\`A6>)?_EK0`?\(%H7
M_/QXC_\`"L\2_P#RUH`/^$"T+_GX\1_^%9XE_P#EK0`?\(%H7_/QXC_\*SQ+
M_P#+6@`_X0+0O^?CQ'_X5GB7_P"6M`!_P@6A?\_'B/\`\*SQ+_\`+6@`_P"$
M"T+_`)^/$?\`X5GB7_Y:T`'_``@6A?\`/QXC_P#"L\2__+6@`_X0+0O^?CQ'
M_P"%9XE_^6M`!_P@6A?\_'B/_P`*SQ+_`/+6@`_X0+0O^?CQ'_X5GB7_`.6M
M`!_P@6A?\_'B/_PK/$O_`,M:`#_A`M"_Y^/$?_A6>)?_`):T`'_"!:%_S\>(
M_P#PK/$O_P`M:`#_`(0+0O\`GX\1_P#A6>)?_EK0`?\`"!:%_P`_'B/_`,*S
MQ+_\M:`#_A`M"_Y^/$?_`(5GB7_Y:T`'_"!:%_S\>(__``K/$O\`\M:`#_A`
MM"_Y^/$?_A6>)?\`Y:T`'_"!:%_S\>(__"L\2_\`RUH`/^$"T+_GX\1_^%9X
ME_\`EK0`?\(%H7_/QXC_`/"L\2__`"UH`/\`A`M"_P"?CQ'_`.%9XE_^6M`!
M_P`(%H7_`#\>(_\`PK/$O_RUH`/^$"T+_GX\1_\`A6>)?_EK0`?\(%H7_/QX
MC_\`"L\2_P#RUH`/^$"T+_GX\1_^%9XE_P#EK0`?\(%H7_/QXC_\*SQ+_P#+
M6@#KK>!+6W@MHC(8[:&*",S2R3RE(46-#+/,S232;5&YW9F8Y+$DDT`34`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
E0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
